ArticleFrontiers in medicine2026
Nomogram integrating BRAF V600E, serum biomarkers, and ultrasound features for malignancy risk stratification in C-TIRADS category 3 and 4 thyroid nodules.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For patients with C-TIRADS 3 or 4 nodules who have undergone fine-needle aspiration cytology (FNAC), subsequent management decisions remain challenging, especially when cytological results are discordant with imaging findings or indeterminate. We built a nomogram incorporating BRAF V600E, serum biomarkers, and ultrasound features to provide an individualized risk estimate of malignancy for these nodules. Methods: We retrospectively included 300 patients with C-TIRADS 3 or 4 nodules. All nodules were confirmed by postoperative pathology or cytology. Among these, 76 were malignant and 224 benign. After running LASSO regression with 10-fold cross-validation and applying the 1-standard error rule to select core predictors, we built the nomogram using Firth-penalized logistic regression. Internal validity was checked using bootstrap resampling with 1,000 iterations while the model's performance was evaluated using ROC curves, calibration (Hosmer-Lemeshow test, Brier score) and decision curve analysis (DCA). The additional predictive value beyond the C-TIRADS system was measured by the Net Reclassification Index (NRI) and the Integrated Discrimination Improvement (IDI). Results: Five independent predictors were finally selected: BRAF V600E mutation (OR = 36.455, 95% CI: 13.381-118.094), TgAb positivity (OR = 4.808, 95% CI: 2.289-10.486), microcalcifications (OR = 4.168, 95% CI: 1.880-9.424), aspect ratio > 1 (OR = 3.027, 95% CI: 1.285-7.115), and serum VEGF (per 100 pg/mL increase, OR = 3.798, 95% CI: 1.763-8.677). Each predictor was independently associated with malignancy (all Conclusion: The nomogram demonstrated good discriminative performance in C-TIRADS 3 or 4 nodules, supporting its utility as a post-FNAC decision aid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.